Publications by authors named "C Grande"
Purpose: The objective of this study is to present the largest personal series of oral teratomas already published in English literature and discuss the diagnosis, neonatal management, and surgical treatment of this disorder.
Method: The study included patients treated by the senior author (RSF) between 2004 and 2023. Data were collected regarding prenatal evaluation, perinatal approach, surgical management, evolution, and treatment of secondary deformities.
Article Synopsis
- Wind energy is important for fighting climate change, but bird collisions with wind turbines can harm bird populations.
- A study using GPS data from 275 raptors in Europe aimed to understand how turbine height and rotor size affect these collision risks.
- Results showed that increasing turbine height decreased collision risk for most birds but increased it for the Short-toed Eagle, while larger rotor diameters increased risks across species, highlighting the need to tailor turbine designs based on local bird populations.
The prevalence of sarcopenia (loss of muscle strength, mass and function) in individuals with heart failure (HF) stands at a considerable level (approximately 20%), contributing to heightened mortality rates and diminished quality of life. The underlying pathophysiological mechanisms involve the presence of low-grade inflammation and a disturbance of the anabolic-catabolic protein balance. The nutritional assessment of patients with HF is a key aspect, and diverse diagnostic tools are employed based on patient profiles (outpatient, inpatient and nursing home).
View Article and Find Full Text PDFArticle Synopsis
- Infection is a major cause of death in multiple myeloma (MM), leading researchers to analyze immune profiles of MM patients compared to healthy individuals.
- The study found significant changes in the distribution of immune cell types in MM patients, particularly in B cells and T cells, which affected their response to COVID-19 vaccination.
- Results suggested that specific immune cell metrics, such as B-cell percentages and counts, can serve as biomarkers to tailor vaccination schedules for MM patients.
Purpose: This phase II clinical trial evaluated the combination of ibrutinib with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in patients with nongerminal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL).
Patients And Methods: The IBDCL trial (NCT02692248) included patients with histologic diagnosis of non-GCB DLBCL with relapsed or refractory disease and non-candidates for stem-cell transplantation. Patients received an induction treatment consisting of six or eight cycles of R-GemOx at standard doses every 2 weeks, in combination with ibrutinib (560 mg daily), followed by a maintenance treatment with ibrutinib for a maximum of 2 years.